This post was originally published on this site

SAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) — The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: FBIO shares.

Investors, who purchased shares of Fortress Biotech, Inc. prior to December 11, 2019 and continue to hold any of their NASDAQ: FBIO shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On November 27, 2020, a lawsuit was filed against Fortress Biotech, Inc. over alleged violations of securities laws. The plaintiff alleged that the Defendants made false and/or misleading statements and/or failed to disclose that IV Tramadol was not safe for the intended patient population, that as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased Fortress Biotech, Inc. (NASDAQ: FBIO) shares should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
mail@shareholdersfoundation.com 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.